Chris Sandburg
Recent Articles by Chris Sandburg
- The 3CL Secret to Pfizer's and Todos Medical’s Success
- Picking a Bottom in CytoDyn - Right Now
- Atea Failure Leaves Todos Medical (TOMDF) Last Man Standing in Oral Antivirals
- Todos Medical (TOMDF) COVID-19 Oral Antiviral Takes Death off Table
- Moderna’s (MRNA) Bloated Market Cap & mRNA Vaccine Thesis Under Fire
- CytoDyn (CYDY) Shorts Throttle Up Bashing Ahead of August Super News Cycle
- CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)
- CytoDyn (CYDY) at Crossroads: Past and Current Leadership Collide in Epic Grudgematch
- Enzolytics (ENZC) Takes on HIV Heavyweight Gilead Sciences
- Todos Medical (TOMDF) with a $22 Million Market Cap Taking on Pharma Giant Pfizer for COVID-19 Antiviral
Recent Comments by Chris Sandburg
- "The essence of your argument seems to be centered around expectations. NP has clearly missed some self imposed deadlines, but these misses pale in co" on CytoDyn’s Preliminary Phase 1b/2 Cancer Results Likely to Receive Breakthrough Therapy Designation (BTD)